Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Detailed methods of the VOYAGE 2 trial (NCT02207244), including details of randomization, treatment allocation, and blinding, have been published previously [16]. In brief, VOYAGE 2 was a phase III, multicenter, randomized, double-blind clinical trial conducted in 115 sites across 9 countries (USA, Canada, Poland, Czech Republic, Germany, Spain, Russia, Australia, and South Korea) from November 2014 to May 2016 and reached planned completion.
There is a need for a well-tolerated and effective bDMARD therapy for PsA that can be confidently utilised for older patients with multiple potential comorbidities. In patients taking ustekinumab, fewer AEs were observed over 3 years for younger versus older patients with PsA and ustekinumab was effective in both age groups (< 60 years vs ≥ 60 years). Persistence was numerically higher in the older age group.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
